A Real-World Study: Evaluating Long-Term Mortality in Patients Treated by High-Dose PCBA vs POBA

Roundtable Discussion

Prof Konstantinos Donas (St Franziskus Hospital, DE) meets with Prof Frank Vermassen (University of Ghent, BE) and Dr Gergana Taneva (University Hospital Ramón y Cajal, ES) to discuss the latest results from his 5-year, real-world study: Evaluating long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon angioplasty (PCBA) versus plain balloon angioplasty (POBA)


Highlights of this short 10-min roundtable include; a discussion on the use of paclitaxel and it's impact on mortality, an overview of the real-world study results vs related randomised control trial studies and the imapct these have on a surgeon's daily practice, as well as a disucussion around treatment strategies and the importance of further studies in this important field of medicine.  New real world study evaluating long-term mortality of paclitaxel-coated balloon angioplasty


Filmed by Radcliffe Vascular during CIRSE 2019.

Videographer: Tom Brown, Dave Good

A real-world study: Evaluating long-term mortality of patients treated by high-dose PCBA vs POBA
Prof K Donas, St Franziskus Hospital, Münster University Hospital, DE
Prof F Vermassen, University of Ghent, Ghent, BE
Dr G Taneva, University Hospital Ramón y Cajal, Madrid, ES
Watch Interview:

10.42 mins